Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (52)
  • Open Access

    ARTICLE

    Implementation of Psychosocial Intervention StomieCare for Patients with Rectal Cancer Treated by Rectal Excision and Temporary Stoma: A Pilot Study of Feasibility, Acceptability and Efficacy

    Implémentation d’une intervention psychosociale StomieCare auprès de patients opérés d’un cancer du rectum avec stomie temporaire : une étude pilote de faisabilité, d’acceptabilité et d’efficacité

    Stéphane Faury1,*, Katia M’Bailara1,2, Eric Rullier3, Quentin Denost4, Bruno Quintard1

    Psycho-Oncologie, Vol.17, No.3, pp. 147-157, 2023, DOI:10.32604/po.2023.044901

    Abstract Objective: This study aims to evaluate the feasibility, acceptability, and efficacy of StomieCare for rectal cancer patients undergoing surgery with a temporary stoma. StomieCare (three individual sessions) comprises thematic discussions, information and education, and teaching problem-solving and cognitive restructuring. Methods: Thirty-seven rectal cancer participants treated by surgery and temporary stoma were recruited and randomized to control (routine care approach, n = 20) and intervention (routine care and StomieCare, n = 17) groups. Outcomes were psychological distress (anxiety and depression, HADS), body image (BIS, ESS), and quality of life (FACT-C), at one week before surgery (T1) and 3 months after stoma… More >

  • Open Access

    ARTICLE

    Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

    SUNG HEE LIM1,#, HEE JIN CHO1,2,3,#, KYOUNG-MEE KIM4, HO YEONG LIM1, WON KI KANG1, JEEYUN LEE1, YOUNG SUK PARK1, HEE CHEOL KIM5,*, SEUNG TAE KIM1,*

    Oncology Research, Vol.31, No.6, pp. 855-866, 2023, DOI:10.32604/or.2023.030374

    Abstract Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The molecular analysis comprised whole-exome sequencing, ribonucleic acid sequencing, and a methylation array on patient tissues. Results: Genomic and molecular characterization was successfully conducted in 103 patients. Six of 103 CRC samples were hypermutated, and none of the non-hypermutant tumors were microsatellite unstable. Among those 103 patients, 89… More >

  • Open Access

    ARTICLE

    MiR-520f-3p inhibits epithelial-mesenchymal transition of colorectal cancer cells by targeting Yes-associated protein 1

    LIJUN JIANG1, WENMIN JI1, YAJIE GONG2, JIAJUN LI2, JINCHUN LIU1,*

    BIOCELL, Vol.47, No.8, pp. 1803-1810, 2023, DOI:10.32604/biocell.2023.029516

    Abstract Background: Colorectal cancer (CRC) is one of the most common malignancies. Early diagnosis is the key to effective treatment of CRC. Since microRNAs (miRNAs) can be used as biomarkers of CRC, the objective of this work was to examine the effect of miR-520f-3p, which targets YAP1 (Yes-associated protein 1), on the ability of CRC cells to proliferate, invade, migrate, and undergo epithelial-mesenchymal transition (EMT). Methods: A miR-520f-3p mimic was used to overexpress miR-520f-3p in HT29 cells. To establish the tumor-bearing mouse model, transfected HT29 cells were subcutaneously implanted into BALB/c-nu nude mice, and YAP1 and miR-520f-3p levels were determined using… More > Graphic Abstract

    MiR-520f-3p inhibits epithelial-mesenchymal transition of colorectal cancer cells by targeting Yes-associated protein 1

  • Open Access

    ARTICLE

    Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study

    SUKRAN SENYUREK1, SEZER SAGLAM2,*, ESRA KAYTAN SAGLAM3, HAKAN YANAR4, KAAN GOK4, DIDEM TASTEKIN5, CANAN KOKSAL AKBAS6, NERGIZ DAGOGLU SAKIN3, GULBIZ DAGOGLU KARTAL7, EMRE BALIK8, METIN KESKIN4, YASEMIN SANLI9, MINE GULLUOGLU10, ZULEYHA AKGUN11

    Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351

    Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of LARC. The prescribed dose was… More >

  • Open Access

    ARTICLE

    The zinc figure protein ZNF575 impairs colorectal cancer growth via promoting p53 transcription

    NING AN1,#, HEQING PENG2,#, MIN HOU3, DUOFENG SU2, LIU WANG4, XIAOGANG SHEN5,*, MING ZHANG1,*

    Oncology Research, Vol.31, No.3, pp. 307-316, 2023, DOI:10.32604/or.2023.028564

    Abstract Zinc-finger proteins play different roles in cancer; however, the function of zinc-finger protein ZNF575 in cancer remains unclear. In the present study, we aimed to determine the function and expression of ZNF575 in colorectal cancer. Proliferation assay, colony formation assay, and tumor model in mice were used to investigate the function of ZNF575 after ectopic expression of ZNF575 in colorectal cancer (CRC) cells. RNA sequencing, ChIP, and luciferase assays were used to investigate the mechanism behind ZNF575 regulation of CRC cell growth. The expression of ZNF575 was determined by IHC staining in 150 pairs of malignant CRC tissues, followed by… More > Graphic Abstract

    The zinc figure protein ZNF575 impairs colorectal cancer growth via promoting p53 transcription

  • Open Access

    ARTICLE

    Rectal Cancer Stages T2 and T3 Identification Based on Asymptotic Hybrid Feature Maps

    Shujing Sun1,3, Jiale Wu2, Jian Yao1, Yang Cheng4, Xin Zhang1, Zhihua Lu3, Pengjiang Qian1,*

    CMES-Computer Modeling in Engineering & Sciences, Vol.137, No.1, pp. 923-938, 2023, DOI:10.32604/cmes.2023.027356

    Abstract Many existing intelligent recognition technologies require huge datasets for model learning. However, it is not easy to collect rectal cancer images, so the performance is usually low with limited training samples. In addition, traditional rectal cancer staging is time-consuming, error-prone, and susceptible to physicians’ subjective awareness as well as professional expertise. To settle these deficiencies, we propose a novel deep-learning model to classify the rectal cancer stages of T2 and T3. First, a novel deep learning model (RectalNet) is constructed based on residual learning, which combines the squeeze-excitation with the asymptotic output layer and new cross-convolution layer links in the… More >

  • Open Access

    ARTICLE

    Macrophage-derived SHP-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals

    XUELIANG WU1,#, SHAOYU GUAN2,#, YONGGANG LU3, JUN XUE4, XIANGYANG YU1, QI ZHANG5,*, XIMO WANG1,5,*, TIAN LI6

    Oncology Research, Vol.31, No.2, pp. 125-139, 2023, DOI:10.32604/or.2023.028657

    Abstract This research aimed to explore the influence of Src homology-2 containing protein tyrosine phosphatase (SHP- 2) on the functions of tyrosine kinase receptors with immunoglobulin and EGF homology domains 2 (Tie2)-expressing monocyte/macrophages (TEMs) and the influence of the angiopoietin(Ang)/Tie2-phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) (Ang/Tie2-PI3K/Akt/mTOR) signaling pathway on the tumor microvascular remodeling in an immunosuppressive microenvironment. In vivo, SHP-2- deficient mice were used to construct colorectal cancer (CRC) liver metastasis models. SHP-2-deficient mice had significantly more metastatic cancer and inhibited nodules on the liver surface than wild-type mice, and the high-level expression of p-Tie2 was found in… More > Graphic Abstract

    Macrophage-derived SHP-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals

  • Open Access

    ARTICLE

    LSM12 facilitates the progression of colorectal cancer by activating the WNT/CTNNB1 signaling pathway

    YAN ZHUANG1,#, CHUNLAN NING2,3,#, PENGFEI LIU4,#, YANPENG ZHAO5, YUE LI6, ZHENCHI MA6, LULING SHAN6, YINGZHE PIAO7, PENG ZHAO6,*, XUN JIN2,*

    Oncology Research, Vol.30, No.6, pp. 289-300, 2022, DOI:10.32604/or.2022.028225

    Abstract Aberrant activation of the WNT signaling pathway is a joint event in colorectal cancer (CRC), but the molecular mechanism is still unclear. Recently, RNA-splicing factor LSM12 (like-Sm protein 12) is highly expressed in CRC tissues. This study aimed to verify whether LSM12 is involved in regulating CRC progression via regulating the WNT signaling pathway. Here, we found that LSM12 is highly expressed in CRC patient-derived tissues and cells. LSM12 is involved in the proliferation, invasion, and apoptosis of CRC cells, similar to the function of WNT signaling in CRC. Furthermore, protein interaction simulation and biochemical experiments proved that LSM12 directly… More >

  • Open Access

    REVIEW

    The remodeling roles of lipid metabolism in colorectal cancer cells and immune microenvironment

    JIATENG ZHONG1,2, JINGYU GUO1, XINYU ZHANG1, SHUANG FENG1, WENYU DI2, YANLING WANG3,*, HUIFANG ZHU1,*

    Oncology Research, Vol.30, No.5, pp. 231-242, 2022, DOI:10.32604/or.2022.027900

    Abstract Lipid is a key component of plasma membrane, which plays an important role in the regulation of various cell biological behaviors, including cell proliferation, growth, differentiation and intracellular signal transduction. Studies have shown that abnormal lipid metabolism is involved in many malignant processes, including colorectal cancer (CRC). Lipid metabolism in CRC cells can be regulated not only by intracellular signals, but also by various components in the tumor microenvironment, including various cells, cytokines, DNA, RNA, and nutrients including lipids. In contrast, abnormal lipid metabolism provides energy and nutrition support for abnormal malignant growth and distal metastasis of CRC cells. In… More >

  • Open Access

    ARTICLE

    Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy

    YUNG-SUNG YEH1,2,3, HSIANG-LIN TSAI4,5, YEN-CHENG CHEN4,6, WEI-CHIH SU4,6, PO-JUNG CHEN4,6, TSUNG-KUN CHANG4,6,7, CHING-CHUN LI4, CHING-WEN HUANG4,5, JAW-YUAN WANG4,5,6,8,9,10,*

    Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659

    Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response, progression-free survival (PFS), overall survival… More >

Displaying 1-10 on page 1 of 52. Per Page